Breaking News Instant updates and real-time market news.

SBBP

Strongbridge Biopharma

$6.60

-0.25 (-3.65%)

, DISCA

Discovery

$23.00

-0.6 (-2.54%)

10:36
08/11/17
08/11
10:36
08/11/17
10:36

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Strongbridge Biopharma (SBBP) initiated with an Outperform at Oppenheimer. 2. Discovery (DISCA) initiated with a Neutral at Piper Jaffray. 3. MannKind (MNKD) initiated with a Buy at Maxim. 4. Veritone (VERI) initiated with a Buy at Roth Capital. 5. Esperion (ESPR) initiated with a Neutral at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

SBBP

Strongbridge Biopharma

$6.60

-0.25 (-3.65%)

DISCA

Discovery

$23.00

-0.6 (-2.54%)

MNKD

MannKind

$1.16

0.01 (0.87%)

VERI

Veritone

$8.02

-0.65 (-7.50%)

ESPR

Esperion

$48.14

-2.4 (-4.75%)

  • 10

    Aug

SBBP Strongbridge Biopharma
$6.60

-0.25 (-3.65%)

08/10/17
OPCO
08/10/17
INITIATION
Target $12
OPCO
Outperform
Strongbridge Biopharma initiated with an Outperform at Oppenheimer
Oppenheimer analyst Hartaj Singh started Strongbridge Biopharma with an Outperform rating and $12 price target. The company's two assets, Keveyis and Recorlev, both have "proven clinical data and prior use in their respective therapeutic categories," the analyst contends. He's "bullish on the story."
12/28/16
JMPS
12/28/16
NO CHANGE
JMPS
Strongbridge Biopharma is roughly '$140M opportunity,' says JMP Securities
After Strongbridge acquired rare disease drug Keveyis, JMP Securities analyst Liisa Bayko estimates that the drug is worth about $140M. The analyst continues to recommends Stonebridge's stock ahead of the 2017 launch of Keveyis in 2017 and the Phase 3 data on its COR-003 drug in early 2018. She reiterates a $10 price target and an Outperform rating on the stock.
01/25/17
HCWC
01/25/17
NO CHANGE
Target $18
HCWC
Buy
Strongbridge Biopharma price target raised to $18 from $15 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for Strongbridge Biopharma to $18 saying he sees improved commercial and regulatory strengths heading into 2017. The investment thesis is "fundamentally much stronger now than before from a long-term perspective, especially at the current discounted valuation," Fein tells investors in a research note. The analyst sees a clear path for COR-003 approval and he reiterates a Buy rating on Strongbridge shares.
DISCA Discovery
$23.00

-0.6 (-2.54%)

08/11/17
PIPR
08/11/17
INITIATION
Target $27
PIPR
Neutral
Discovery initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Stan Meyers started Discovery Communications with a Neutral rating and $27 price target. The company's "heavy reliance" on affiliate fees makes a pivot towards skinny bundles challenging, the analyst contends.
08/01/17
ARGS
08/01/17
DOWNGRADE
ARGS
Hold
Scripps Networks downgraded to Hold from Buy at Argus
Argus analyst Joseph Bonner downgraded Scripps (SNI) following its acquisition by Discovery Communications (DISCA).
08/01/17
SBSH
08/01/17
UPGRADE
SBSH
Neutral
Scripps Networks upgraded to Neutral from Sell at Citi
Citi analyst Jason Bazinet upgraded Scripps Networks (SNI) to Neutral following its acquisition by Discovery Communications (DISCA). The analyst this morning also upgraded Discovery to Buy.
08/08/17
PIVT
08/08/17
UPGRADE
Target $28
PIVT
Buy
Discovery upgraded to Buy after post-Scripps deal weakness at Pivotal Research
Pivotal Research analyst Brian Wieser upgraded Discovery (DISCA) to Buy from Hold in light of the stock's recent weakness following its deal to acquire Scripps Networks (SNI). While the "advantages of this combination should not be overstated," Wieser expects that a combined company may perform slightly better in the national TV upfront markets and he notes the guidance for $350M in annual cost synergies after 2019. Wieser keeps a $28 price target on Discovery shares, which have declined about 9.5% since July 31, the day the company confirmed its deal to buy Scripps.
MNKD MannKind
$1.16

0.01 (0.87%)

05/11/17
PIPR
05/11/17
NO CHANGE
Target $0.54
PIPR
Underweight
MannKind sales of Afrezza remain slow, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says sales of MannKind's Afrezza "failed to meaningfully inflect" in Q1 despite new commercialization initiatives. The company continues to drain its cash, Schimmer tells investors in a post-earnings research note. He reiterates an Underweight rating on MannKind with a 54c price target.
08/11/17
MAXM
08/11/17
INITIATION
Target $4
MAXM
Buy
MannKind initiated with a Buy at Maxim
Maxim analyst Jason Kolbert started MannKind with a Buy rating and $4 price target, stating that the relaunch of Afrezza is building traction. A "conservative" 5% share of the U.S. insulin market is a $350M opportunity for Afrezza, added Kolbert.
VERI Veritone
$8.02

-0.65 (-7.50%)

06/06/17
NORL
06/06/17
INITIATION
Target $19
NORL
Outperform
Veritone initiated with an Outperform at Northland
Northland analyst Michael Latimore started Veritone with an Outperform rating and $19 price target.
08/11/17
ROTH
08/11/17
INITIATION
Target $13.2
ROTH
Buy
Veritone initiated with a Buy at Roth Capital
Roth Capital analyst Brian Alger started Veritone with a Buy rating and $13.20 price target, calling it the "only pure play publicly-traded Artificial Intelligence platform." With about 70 third party cognitive engines already validated and running, Veritone has a first-mover advantage over its single engine and/or closed system AI peers, Alger tells investors.
06/06/17
CHLM
06/06/17
INITIATION
Target $22
CHLM
Buy
Veritone initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Chad Bennett initiated Veritone with a Buy rating $22 price target, identifying the stock as a "unique" opportunity to get in on the ground floor of a high-growth Artificial Intelligence company. The company, whose platform allows unstructured video/audio data to be processed and analyzed, is a "bet on the AI market, not on any individual solution, Bennett tells investors.
06/06/17
WDLK
06/06/17
INITIATION
Target $18
WDLK
Buy
Veritone initiated with a Buy at Wunderlich
Wunderlich analyst William Choistarted Veritone with a Buy rating and $18 price target.
ESPR Esperion
$48.14

-2.4 (-4.75%)

08/09/17
08/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Transocean (RIG) upgraded to Neutral from Sell at Goldman Sachs with analyst Waqar Syed saying Transocean has enhanced the balance sheet over the past several months and now sees leveraged metrics to be relatively better than the peer group in the 2019/2020 time frame. 2. Ralph Lauren (RL) upgraded to Neutral from Underweight at Atlantic Equities. 3. Brink's (BCO) upgraded to Outperform from In-Line at Imperial Capital with analyst Jeff Kessler saying investors have "much to be bullish about" in the second half of 2017 following the company's "strong" first half results and recent acquisitions. 4. Novavax (NVAX) upgraded to Buy from Neutral at Ladenburg with analyst Kevin Degeeter saying he believes the company's NanoFlu could become a "potent vaccine" for prevention of seasonal influenza. 5. Esperion (ESPR) upgraded to Buy from Hold at Jefferies with analyst Michael Yee saying the shares are likely "to keep grinding higher and higher" following the "new de-risking data" for the triple combination. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/09/17
JEFF
08/09/17
UPGRADE
Target $85
JEFF
Buy
Esperion upgraded to Buy with $85 price target at Jefferies
Jefferies analyst Michael Yee last night upgraded Esperion Therapeutics to Buy from Hold and raised his price target for the shares to $85 from $55. The shares are likely "to keep grinding higher and higher" following the "new de-risking data" for the triple combination, Yee tells investors in a research note. The analyst sees potential partnership opportunities as a "big catalyst."
08/08/17
JEFF
08/08/17
UPGRADE
JEFF
Buy
Esperion upgraded to Buy from Hold at Jefferies
08/11/17
BOFA
08/11/17
INITIATION
BOFA
Neutral
Esperion initiated with a Neutral at BofA/Merrill
BofA/Merrill analyst Ying Huang reinstated Esperion with Neutral saying Bernpedoic acid is approvable with LDL lowering but there are regulatory risks.

TODAY'S FREE FLY STORIES

SPX

S&P 500

06:00
08/23/17
08/23
06:00
08/23/17
06:00
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$73.16

1.01 (1.40%)

05:59
08/23/17
08/23
05:59
08/23/17
05:59
Hot Stocks
Microsoft unveils Project Brainwave for real-time AI »

Microsoft engineer Doug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

GDX

Market Vector Gold Miners

$23.09

-0.22 (-0.94%)

05:57
08/23/17
08/23
05:57
08/23/17
05:57
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$122.21

-0.55 (-0.45%)

05:57
08/23/17
08/23
05:57
08/23/17
05:57
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRAM

Everspin Technologies

$15.22

0.3 (2.01%)

05:57
08/23/17
08/23
05:57
08/23/17
05:57
Hot Stocks
Everspin Technologies names Kevin Conley as CEO, effective September 1 »

Everspin Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

NUGT

Direxion Gold Miners Bull

$32.79

-0.86 (-2.56%)

05:57
08/23/17
08/23
05:57
08/23/17
05:57
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$18.22

-0.58 (-3.09%)

05:56
08/23/17
08/23
05:56
08/23/17
05:56
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$26.31

0.61 (2.37%)

05:56
08/23/17
08/23
05:56
08/23/17
05:56
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$60.10

1.74 (2.98%)

05:56
08/23/17
08/23
05:56
08/23/17
05:56
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$47.36

-3.72 (-7.28%)

05:55
08/23/17
08/23
05:55
08/23/17
05:55
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$82.37

5.27 (6.84%)

05:55
08/23/17
08/23
05:55
08/23/17
05:55
Technical Analysis
VelocityShares Daily Inverse VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$16.79

-2.75 (-14.07%)

05:54
08/23/17
08/23
05:54
08/23/17
05:54
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVXY

ProShares Short VIX Short-Term Futures

$78.87

5.4 (7.35%)

05:54
08/23/17
08/23
05:54
08/23/17
05:54
Technical Analysis
ProShares Short VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$9.77

0.06 (0.62%)

05:54
08/23/17
08/23
05:54
08/23/17
05:54
Technical Analysis
United States Oil Fund: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOP

SPDR Oil Exploration and Production Fund

$29.34

0.25 (0.86%)

05:53
08/23/17
08/23
05:53
08/23/17
05:53
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$25.16

0.58 (2.36%)

05:52
08/23/17
08/23
05:52
08/23/17
05:52
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGAZ

VelocityShares 3x Long Natural Gas ETN

$12.14

-0.29 (-2.33%)

05:52
08/23/17
08/23
05:52
08/23/17
05:52
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWZ

MSCI Brazil Index

$39.33

0.58 (1.50%)

05:52
08/23/17
08/23
05:52
08/23/17
05:52
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFA

iShares MSCI EAFE Index Fund

$66.49

0.32 (0.48%)

05:51
08/23/17
08/23
05:51
08/23/17
05:51
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNK

SPDR Barclays High Yield Bond

$37.02

0.17 (0.46%)

05:51
08/23/17
08/23
05:51
08/23/17
05:51
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJB

ProShares Short High Yield

$23.44

-0.12 (-0.51%)

05:51
08/23/17
08/23
05:51
08/23/17
05:51
Technical Analysis
ProShares Short High Yield: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HYG

iShares iBoxx $ High Yield Corporate Bond

$87.92

0.36 (0.41%)

05:50
08/23/17
08/23
05:50
08/23/17
05:50
Technical Analysis
iShares iBoxx $ High Yield Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$120.70

-0.12 (-0.10%)

05:50
08/23/17
08/23
05:50
08/23/17
05:50
Technical Analysis
iShares iBoxx $ Investment Grade Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLT

iShares 20+ Year Treasury Bond Fund

$126.44

-0.49 (-0.39%)

05:50
08/23/17
08/23
05:50
08/23/17
05:50
Technical Analysis
iShares 20+ Year Treasury Bond Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLV

iShares Silver Trust

05:49
08/23/17
08/23
05:49
08/23/17
05:49
Technical Analysis
iShares Silver Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.